TSE:4523Pharmaceuticals
Eisai (TSE:4523) Following Leqembi Home Dosing Approval Is The Alzheimer’s Upside Already Priced In
Eisai (TSE:4523) is back in focus after fresh Alzheimer’s data and a new at-home dosing option for Leqembi. These developments together reshape how investors might think about the company’s neurology franchise.
See our latest analysis for Eisai.
Eisai’s latest Alzheimer’s updates arrive alongside a 12.12% 1 month share price return, though the share price is still down 7.04% year to date, while the 1 year total shareholder return of 16.39% contrasts with weaker 3 and 5 year total shareholder...